Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Type-I interferons and systemic lupus erythematosus.

Sophie Koutouzov1, Alexis Mathian, Ali Dalloul

  • 1INSERM U 764 and Université Paris XI, 32 Rue des Carnets, Clamart, France. sophie.koutouzov@inserm.ipsc.u-psud.fr

Autoimmunity Reviews
|October 10, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of a Relapsing Polychondritis disease-specific Quality of Life instrument (ERN ReCONNET RP-QoL).

Rheumatology (Oxford, England)·2026
Same author

Association between cumulative glucocorticoid exposure and epicardial adipose tissue volume in systemic lupus erythematosus.

EULAR rheumatology open·2026
Same author

Ring-like late gadolinium enhancement pattern in antimalarial-induced cardiomyopathy.

European heart journal. Case reports·2026
Same author

Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.

Cell·2026
Same author

Serum lipidomic and metabolomic signatures link epicardial adipose tissue to cardiovascular diseases in SLE: a post-hoc analysis.

Lupus science & medicine·2026
Same author

Severe thrombocytopenia in antiphospholipid syndrome: a retrospective study of 432 patients.

RMD open·2026
Same journal

Reflections on chromatin structures, corresponding autoantibodies - And conflicting dogmas impacting pathogenesis of lupus nephritis.

Autoimmunity reviews·2026
Same journal

Cancer-associated dermatomyositis: A scoping review of the literature.

Autoimmunity reviews·2026
Same journal

The landscape of serum autoantibodies in lupus nephritis.

Autoimmunity reviews·2026
Same journal

Altered reproductive hormone profiles in systemic lupus erythematosus - A systematic review and meta-analysis.

Autoimmunity reviews·2026
Same journal

Decoding gut microbiome alterations in celiac disease: Implications for pathogenesis and treatment.

Autoimmunity reviews·2026
Same journal

Rethinking immunosuppression in limited cutaneous systemic sclerosis. The lcSSc conundrum; pros and cons for a timely immunosuppressive treatment.

Autoimmunity reviews·2026
See all related articles

Systemic lupus erythematosus (SLE) involves autoantibodies and inflammation. Type-I interferons, particularly IFNalpha, are now recognized as key drivers, linking B-cell expansion to immune activation and tissue damage, presenting a new therapeutic target.

Area of Science:

  • Immunology
  • Rheumatology
  • Genetics

Background:

  • Systemic lupus erythematosus (SLE) is an autoimmune disease involving autoantibodies against nuclear antigens and chronic inflammation.
  • Genetic factors contribute to SLE, allowing self-reactive B-cells to evade normal immune control.
  • T-cell help is crucial for the development of SLE, alongside autoimmune B-cells.

Purpose of the Study:

  • To investigate the role of type-I interferons (IFNs), specifically IFNalpha, in the pathogenesis of SLE.
  • To establish IFNalpha as a significant factor in SLE based on patient and mouse model data.
  • To explore IFNalpha as a potential therapeutic target for SLE.

Main Methods:

  • Analysis of clinical and laboratory findings in SLE patients.

Related Experiment Videos

  • Examination of data from SLE-prone mouse models.
  • Interpretation of observed symptoms and findings as downstream effects of IFNalpha production.

    • Main Results:

    • IFNalpha is identified as a major contributor to SLE pathogenesis.
    • IFNalpha acts as a link between autoimmune B-cell expansion and the activation of other immune components.
    • A cycle of immune activation, inflammation, and tissue damage, particularly in the kidney, is associated with high IFNalpha levels.

    Conclusions:

    • IFNalpha plays a central role in SLE, connecting B-cell abnormalities to broader immune system stimulation.
    • The findings support the concept of a self-perpetuating inflammatory cycle in SLE driven by IFNalpha.
    • IFNalpha represents a promising new therapeutic target for managing SLE.